— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected. — Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US. — For full-year 2020, Amarin […]
— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected. — Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US. — For full-year 2020, Amarin […]
— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.
— Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US.
— For full-year 2020, Amarin expects revenues to be $650 million to $700 million.
— AMRN shares gained 2% during the aftermarket hours.
